Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by TimboBagginson Sep 20, 2024 10:03am
89 Views
Post# 36232916

RE:Smaller Deals

RE:Smaller Deals

DeathXray33 wrote:
Big Drugmakers Are Clinching Smaller Deals J&J, Merck and others are focusing on targets costing $5 billion or less, curtailing pricier acquisitions to help smooth regulators approval Aug. 12, 2024 5:30 am ET Merck has made four small acquisitions this year to diversify and deepen the companys drug pipeline. For years the worlds biggest drugmakers paid up for deals. Now they are writing much smaller checks. After shelling out tens of billions of dollars for single biotech companies, pharmaceutical giants such as AbbVie ABBV , AstraZeneca and Merck & Co. have shifted to smaller targets costing $5 billion or less. Many of the companies getting taken out are private. ------------------------------------------------ https://www.wsj.com/health/pharma/big-drugmakers-are-clinching-smaller-deals-0c039593?mod=pharma_more_article_pos12

 

5 Billion sounds ok to me 

<< Previous
Bullboard Posts
Next >>